Innovating Antibodies, Improving Lives
Forward looking statement

This presentation contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Further, certain forward looking statements are based upon assumptions of future events which may not prove to be accurate. The forward looking statements in this document speak only as at the date of this presentation. Genmab does not undertake any obligation to update or revise forward looking statements in this presentation nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
On the Road to 2025: Evolving Into a Fully Integrated Biotech

Core Purpose
To improve the lives of patients by creating & developing innovative antibody products

Our Strategy
- Focus on core competence
- Turn science into medicine
- Build a profitable & successful biotech

Vision
By 2025, our own product has transformed cancer treatment and we have a pipeline of knock-your-socks off antibodies

© Genmab
For investor audience only. Not for public information or use. Not for promotional use.
Well Positioned for Future Growth

- Consistent and solid track record
- World-class pipeline & innovation with two potential near-term launches
- Partnerships with innovators and industry leaders
- Strong Financials to invest in growth opportunities

© Genmab
For Investor audience only. Not for public information or use. Not for promotional use.
Consistent, Solid Track Record Fuels Our Growth:
Over 20 Years of Achievements

- 38 Cumulative INDs since 1999
- 22 clinical-stage product candidates based on Genmab’s innovation
- First BLA submission

- Multiple Genmab-created products approved
- 8 Years of profitability & expanding top line
- Investing in our capabilities

- Experienced, international management team
- Dual-listed in US & DK with 2019 US IPO

© Genmab
For investor audience only. Not for public information or use. Not for promotional use.
The Genmab Difference

Strong pipeline of 1st-in-class / best-in-class products

Deep insight into antibody biology & disease targets

Match in-house expertise with strategic partnerships

Proprietary technologies allow us to build a world-class pipeline
Innovative Clinical Pipeline: Genmab Proprietary* and Partnered Products - Most Advanced Development Phase

Phase 1
- DuoBody-CD40x4-1BB
- DuoHexaBody-CD3
- DuoBody-CD3x5T4
- HexaBody-DR5/DR5

Phase 1/2
- DuoBody-PD-L1x4-1BB

Phase 2
- Epcoritamab
- Tisotumab vedotin (BLA submitted)
- Teclistamab
- Talquetamab
- Mim
- Camidanlumab tesirine
- PRV-015

Phase 3
- JNJ-63709178
- JNJ-63898081
- JNJ-67571244
- JNJ-70218902
- HuMax-IL8
- Lu AF82422

Approved‡
- Amivantamab (BLA submitted)
- Daratumumab
- Ofatumumab
- Teprotumumab

*Products where Genmab has ownership of at least 50%
†See local prescribing information for full indications / safety information
§50:50 partnership with BioNTech; ±50:50 partnership with AbbVie; ²Development by Janssen Biotech, Inc; ³Development by BMS; ⁴Development by Lundbeck; ⁵Development by Novo Nordisk, approved in the US; ⁶Development by Horizon Therapeutics, approved in the US; ⁷Development by Provention Bio; ⁸Developed by Seagen; ⁹Development by Novartis; ¹⁰Development by Horizon Therapeutics, approved in the US

© Genmab
For Investor audience only. Not for public information or use. Not for promotional use.
Investing in the Breadth & Depth of our Pipeline

Expanding & maturing trials for our proprietary* assets

R&D Engine: Our Technology Platforms

• DuoBody®
• HexaBody®
• DuoHexaBody®
• HexElect®

* Genmab owned ≥50%; number of active clinical trials >20 expected in 2021
Tisotumab Vedotin in Collaboration with Seagen

First-in-class
- Antibody–drug conjugate (ADC) directed against Tissue Factor (TF)
- Phase 3 study in Recurrent or Metastatic Cervical Cancer (innovaTV 301) recruiting
- BLA submitted, recurrent or metastatic cervical cancer

Very favorable efficacy with manageable safety profile
- Very favorable overall response in Phase 2 innovaTV 204 study vs. prior reported SoC, with manageable safety profile

Broad population in innovaTV 204 study
- Not restricted to biomarker selection
- Pre-treated as per current SoC
- Regardless of histology

In Phase 2 innovaTV 204 study: Tisotumab vedotin demonstrated very favorable, durable responses and a manageable safety profile in 2L+ r/m cervical cancer patients
Epcoritamab in Collaboration with AbbVie

Novel MoA
- Bispecific T cell engager [DuoBody]

Potential best-in-class
- Potential for Improved efficacy & safety

Subcutaneous administration
- Enhanced convenience & ease of administration for HCPs & patients compared to IV infusion

Comprehensive development plan
- Trials in several B-cell malignancies
- Trials across multiple lines of therapy
- Exploration as both monotherapy and in combination

Currently investigated in several clinical trials across B-cell NHL histologies / in various combinations: Phase 3 DLBCL; Phase 2 expansion part ongoing; Phase 1b exploring combinations with multiple SoC treatments
Epcoritamab: Potential Best-in-Class

**Updated Dose-escalation Data Presented at ASH 2020***

**Novel, off-the-shelf therapy with convenient SubQ administration**
- Phase 1/2 study (NCT03625037) in patients with relapsed, progressive or refractory B-cell lymphoma
- RP2D: 48 mg reached with no DLTs; MTD not reached

**Favorable safety profile**
- Supports potential for combination therapies / future outpatient administration
- CRS events were Grade 1 and 2

**Demonstrated substantial single-agent activity in heavily pre-treated patients with B-NHL**
- Patients with DLBCL receiving ≥48 mg:
  - Responses achieved in 10 of 11 evaluable patients, including CR in 6 patients
  - All patients receiving ≥12 mg who achieved CR remain in remission
  - Patients with FL receiving ≥12 mg: ORR was 80%, with 60% CR
  - Encouraging responses, including CR, observed in 2 of 4 evaluable patients with MCL

**Binds to distinct epitope**
- Different from that of rituximab and obinutuzumab:
  - Has potential to be partner of choice in combinations with SoC therapies containing rituximab

---


© Genmab
For Investor audience only. Not for public information or use. Not for promotional use.
**DuoBody-PD-L1x4-1BB (GEN1046) & DuoBody-CD40x4-1BB (GEN1042) in Collaboration with BioNTech**

**GEN1046**
- First-in-class bispecific next generation checkpoint immunotherapy
- Designed to enhance T-cell and NK cell function through conditional 4-1BB co-stimulation
- Simultaneously blocking the PD-L1 axis
- Enhances proliferation and cytokine production of activated T-cells
- Activates immune cells in the tumor-draining lymph nodes
- Induces tumor regression *in vivo*.

**GEN1042**
- First-in-class bispecific antibody
- Designed to conditionally activate both CD40-expressing antigen-presenting cells (APC) and 4-1BB-expressing T cells
- Conditionally activates T cells and APC in the presence of CD40-expressing cells
Earlier Stage Clinical Development

**DuoHexaBody-CD37**
- Combination of DuoBody & HexaBody platforms
- Novel target for hematological malignancies
- Unique MoA
- Dose escalation ongoing
- 50:50 co-development with AbbVie

**DuoBody-CD3x5T4**
- Based on proprietary DuoBody Technology
- CD3 bispecific, T cell mediated cytotoxicity of 5T4+ tumor cells
- 5T4 expressed on multiple solid tumors, limited expression in healthy tissue
- Dose escalation ongoing
- 50:50 co-development with AbbVie

**HexaBody-DR5/DR5**
- First HexaBody in the clinic
- Targets 2 distinct DR5 epitopes
- DR5 clustering & DR5 agonist activity
- Dose escalation ongoing in multiple solid tumors

© Genmab

For investor audience only. Not for public information or use. Not for promotional use.
**Approved Antibody Therapeutics Created by Genmab**

**DARZALEX® (daratumumab) & DARZALEX FASPRO®**
Redefining Treatment of Multiple Myeloma*

Collaboration with Janssen Biotech, Inc.: Genmab entitled to tiered royalty of 12-20% of net sales

DARZALEX FASPRO first and only SubQ CD38 mAb approved in U.S. for treatment of MM & AL amyloidosis

---

**Kesimpta® (ofatumumab)**
Approved in U.S. in Relapsing Multiple Sclerosis*

Collaboration with Novartis: Genmab entitled to royalty of 10% of net sales

First B-cell therapy that can be self-administered by patients at home using Sensoready® autoinjector pen

---

**TEPEZZA® (teprotumumab)**
Approved in U.S. in Thyroid Eye disease (TED)*

Developed and commercialized by Horizon Therapeutics: Genmab entitled to mid single digit royalty of net sales

First and only U.S. FDA-approved medicine for treatment of TED

---

*See local prescribing information for full indication and safety information.
Building Our Capabilities

**Research**
- Track record of success and investing for tomorrow
  - State-of-the-art facilities
  - Novel technologies and formats
  - External innovation

**Development**
- Scaling up to expand from early to late stage
  - Clinical development & operations
  - Disease area expertise
  - Medical Affairs, Safety and Regulatory

**Commercialization**
- Step change in our business
  - Leadership team in place
  - Focus on U.S. & Japan
  - Building expanded team

Enabling functions to support growth & manage risk

Data Sciences to drive insights

© Genmab
# 2021 Guidance: Recurring Revenue Growth and Focused Investments

<table>
<thead>
<tr>
<th>Key Figures</th>
<th>DKKM</th>
<th>~USDM*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>6,800 – 7,500</td>
<td>1,133 – 1,250</td>
</tr>
<tr>
<td>Recurring Revenue</td>
<td>5,300 – 5,900</td>
<td>883 - 983</td>
</tr>
<tr>
<td>Non-Recurring Revenue</td>
<td>1,500 – 1,600</td>
<td>250 - 267</td>
</tr>
<tr>
<td>Operating Expenses</td>
<td>(5,500) – (5,800)</td>
<td>(917) – (967)</td>
</tr>
<tr>
<td>Operating Income</td>
<td>1,000 – 2,000</td>
<td>166 - 333</td>
</tr>
</tbody>
</table>

**DARZALEX® royalties of ~DKK 4.9B to ~DKK 5.3B to drive significant recurring revenue growth**

**Growth in operating expenses driven by expanding and accelerating our clinical pipeline and capabilities**

**Significant underlying profitability**

---

*2021 Guidance – February 23, 2021 / USD 1.00 = DKK 6.00*
# Key 2021 Priorities: Build a Strong Differentiated Product Pipeline & Bring Own Medicines to Market

<table>
<thead>
<tr>
<th>Priority</th>
<th>Targeted Milestones</th>
</tr>
</thead>
</table>
| Bring our own medicines to patients           | - Tisotumab vedotin<sup>1</sup> – U.S. FDA decision on BLA and progress to market  
- Tisotumab vedotin – JNDA submission in cervical cancer  
- Epcoritamab<sup>2</sup> – acceleration & maximization of development program by advancing expansion cohorts and initiating additional Phase 3 trials |
| Build world-class differentiated product pipeline | - DuoBody-PD-L1x4-1BB<sup>3</sup> – expansion cohort data  
- DuoBody-CD40x4-1BB<sup>3</sup> – dose escalation data  
- Tisotumab vedotin – data in other tumor indication  
- Earlier stage products – progress & expand innovative product pipeline |
| Become leading integrated innovation powerhouse | - Operational commercialization model in US & Japan  
- Further strengthen solid financial foundation |

---

1. 50:50 partnership w/ Seagen; 2. 50:50 partnership w/ AbbVie; 3. 50:50 partnership w/ BioNTech
**Successful track record**

<table>
<thead>
<tr>
<th>Focus Areas</th>
<th>Progress</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Strategy</strong></td>
<td><strong>Sustained Execution</strong></td>
</tr>
<tr>
<td>▪ Focus on core competence</td>
<td></td>
</tr>
<tr>
<td>▪ Turn science into medicine</td>
<td></td>
</tr>
<tr>
<td>▪ Build a profitable and successful biotech</td>
<td></td>
</tr>
</tbody>
</table>

**Genmab profile today**

**2025 Vision**
By 2025, our own product has transformed cancer treatment and we have a pipeline of knock-your-socks-off antibodies

**Building fully integrated biotech innovation powerhouse**

- 2 potential near-term Genmab owned product launches
- Imperative to invest
- Remain focused and disciplined
A Leading International Biotech With Large Free Float

• Ordinary shares: Nasdaq Copenhagen, DK
• ADSs: Nasdaq Global Select USA
• Shares world-wide incl: US, DK, NL, UK
• Market Cap:
  – ~ DKK 161bn
  – ~ USD 26bn
• Shares outstanding: ~66M
Successful Network of Collaborations: Broadening Differentiated Antibody Pipeline & Supporting Our Vision

Discovery / Academic Collaborations

Technology Collaborations

Product Partnerships & Collaborations

For Investor audience only. Not for public information or use. Not for promotional use.
Genmab’s Commitment to Society: Building a Socially Responsible & Sustainable Company

Anchored in our Core Purpose, Values & Vision

▪ To improve the lives of patients by creating and developing innovative antibody products
▪ By 2025 our own product has transformed cancer treatment and we have a pipeline of knock-your-socks-off antibodies

Focused on four main areas to guide our programs

▪ Science-Driven Health Innovations
▪ Employee Well-Being & Vitality
▪ Ethics & Transparency
▪ Environment & Community Sustainability

Commitment to UNSDG and Aligned to ESG Priorities

▪ Ensures that Genmab carries out CSR activities effectively & communicates clearly and openly
▪ Focus on Environment, Society and Governance reporting
## Innovation Powerhouse:
Cutting Edge Proprietary Technologies

<table>
<thead>
<tr>
<th>Technology</th>
<th>Principle</th>
<th>Applications</th>
</tr>
</thead>
<tbody>
<tr>
<td>DuoBody</td>
<td>Bispecific antibodies</td>
<td>Dual targeting</td>
</tr>
<tr>
<td>HexaBody</td>
<td>Target-mediated enhanced hexamerization</td>
<td>Enhanced potency</td>
</tr>
<tr>
<td>DuoHexaBody</td>
<td>Bispecific antibodies with target-mediated enhanced hexamerization</td>
<td>Dual targeting + enhanced potency</td>
</tr>
<tr>
<td>HexElect</td>
<td>Two co-dependent antibodies with target-mediated enhanced hexamerization</td>
<td>Dual targeting + enhanced potency &amp; selectivity</td>
</tr>
</tbody>
</table>
# Approved Medicines Created by Genmab

Including Proposed Label Expansions for Marketed Products

<table>
<thead>
<tr>
<th>Product</th>
<th>Target</th>
<th>Developed By</th>
<th>Disease Indications</th>
<th>Most Advanced Development Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>DARZALEX (daratumumab) &amp; DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)</td>
<td>CD38</td>
<td>Janssen (Tiered royalties to Genmab on net global sales)</td>
<td>Multiple myeloma&lt;sup&gt;2&lt;/sup&gt;</td>
<td>Pre-Clinical 1 1/2 2 3 Approved</td>
</tr>
<tr>
<td>Daratumumab</td>
<td></td>
<td></td>
<td>AL Amyloidosis&lt;sup&gt;2&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Non-MM blood cancers</td>
<td></td>
</tr>
<tr>
<td>Kesimpta (ofatumumab)</td>
<td>CD20</td>
<td>Novartis (Royalties to Genmab on net global sales)</td>
<td>Relapsing multiple sclerosis&lt;sup&gt;2&lt;/sup&gt;</td>
<td>Pre-Clinical 1 1/2 3 Approved</td>
</tr>
<tr>
<td>TEPEZZA (teprotumumab-trbw)</td>
<td>IGF-1R</td>
<td>Horizon Therapeutics (under sublicense from Roche, royalties to Genmab on net global sales)</td>
<td>Thyroid eye disease&lt;sup&gt;2&lt;/sup&gt;</td>
<td>Pre-Clinical 1/2 2 3 Approved</td>
</tr>
<tr>
<td>Teprotumumab</td>
<td></td>
<td></td>
<td>Diffuse cutaneous systemic sclerosis</td>
<td></td>
</tr>
</tbody>
</table>

<sup>1</sup>Products developed and marketed by others incorporating Genmab technology and innovation

<sup>2</sup>See local country prescribing information for precise indications
### Innovative Clinical and Pre-Clinical Pipeline
#### Genmab’s Proprietary Products

<table>
<thead>
<tr>
<th>Product</th>
<th>Target</th>
<th>Developed By</th>
<th>Disease Indications</th>
<th>Most Advanced Development Phase</th>
<th>Pre-Clinical</th>
<th>1</th>
<th>1/2</th>
<th>2</th>
<th>3</th>
<th>Approved</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tisotumab vedotin</td>
<td>TF</td>
<td>50:50 Genmab/Seagen</td>
<td>Cervical cancer</td>
<td>BLA submitted</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Ovarian cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Solid tumors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epcoritamab</td>
<td>CD3, CD20</td>
<td>50:50 Genmab/AbbVie</td>
<td>Relapsed/refractory DLBCL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hematological malignancies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>B-cell NHL (combo)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Relapsed/refractory CLL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DuoBody-PD-L1x4-1BB</td>
<td>PD-L1, 4-1BB</td>
<td>50:50 Genmab/BioNTech</td>
<td>Solid tumors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(GEN1046)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DuoBody-CD40x4-1BB</td>
<td>CD40, 4-1BB</td>
<td>50:50 Genmab/BioNTech</td>
<td>Solid tumors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(GEN1042)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HexaBody-DR5/DR5</td>
<td>DR5</td>
<td>Genmab</td>
<td>Solid tumors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(GEN1029)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DuoHexaBody-CD37</td>
<td>CD37</td>
<td>50:50 Genmab/AbbVie</td>
<td>Hematologic malignancies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(GEN3009)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DuoBody-CD3x5T4</td>
<td>CD3, 5T4</td>
<td>50:50 Genmab/AbbVie</td>
<td>Solid tumors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(GEN1044)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HexaBody-CD38</td>
<td></td>
<td>Genmab</td>
<td>Hematologic malignancies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(GEN3014)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 Certain product candidates in development with partners, as noted. 2 Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen Biotech, Inc.
<table>
<thead>
<tr>
<th>Product</th>
<th>Target</th>
<th>Developed By</th>
<th>Disease Indications</th>
<th>Most Advanced Development Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amivantamab (JNJ-61186372)</td>
<td>EGFR, cMet</td>
<td>Janssen</td>
<td>Non-small-cell lung cancer (NSCLC)</td>
<td>1/2</td>
</tr>
<tr>
<td>Teclistamab (JNJ-64007957)</td>
<td>BCMA, CD3</td>
<td>Janssen</td>
<td>Relapsed or refractory MM</td>
<td>2</td>
</tr>
<tr>
<td>PRV-015 (AMG 714)</td>
<td>IL-15</td>
<td>Provention Bio</td>
<td>Celiac disease</td>
<td>Approved</td>
</tr>
<tr>
<td>Camidanlumab tesirine (ADCT-301)</td>
<td>CD25</td>
<td>ADC Therapeutics</td>
<td>Relapsed /Refractory Hodgkin Lymphoma</td>
<td>1/2</td>
</tr>
<tr>
<td>Mim8</td>
<td>FIX(a), FX</td>
<td>Novo Nordisk</td>
<td>Solid tumors</td>
<td>Solid tumors</td>
</tr>
<tr>
<td>Talquetamab (JNJ-64407564)</td>
<td>GPRC5D, CD3</td>
<td>Janssen</td>
<td>Healthy volunteers &amp; hemophilia A</td>
<td>Solid tumors</td>
</tr>
<tr>
<td>JNJ-63709178</td>
<td>CD123, CD3</td>
<td>Janssen</td>
<td>Relapsed or refractory MM</td>
<td>Solid tumors</td>
</tr>
<tr>
<td>JNJ-63898081</td>
<td>PSMA, CD3</td>
<td>Janssen</td>
<td>Acute Myeloid Leukemia (AML)</td>
<td>Solid tumors</td>
</tr>
<tr>
<td>JNJ-67571244</td>
<td>CD33, CD3</td>
<td>Janssen</td>
<td>Relapsed or refractory AML or MDS</td>
<td>Solid tumors</td>
</tr>
<tr>
<td>JNJ-70218902</td>
<td>Undisclosed</td>
<td>Janssen</td>
<td>Solid tumors</td>
<td>Solid tumors</td>
</tr>
<tr>
<td>HuMax-IL8</td>
<td>IL8</td>
<td>BMS</td>
<td>Advanced cancers</td>
<td>Advanced cancers</td>
</tr>
<tr>
<td>Lu AF82422</td>
<td>alpha-Synuclein</td>
<td>Lundbeck</td>
<td>Parkinson’s disease</td>
<td></td>
</tr>
</tbody>
</table>

*Products under development by a third-party incorporating Genmab technology and innovation*
Tisotumab Vedotin in Cervical Cancer
Designed to Address a High Unmet Medical Need

Recurrent or metastatic cervical cancer
- Poor prognosis advanced / recurrent cervical cancer
  - RR standard therapies generally <15%
  - Median OS 6-8 months
- Data ORR & survival after progression on 1L bevacizumab + doublet chemotherapy are limited

Conclusions*
(Previously treated recurrent or metastatic cervical cancer)
- Compelling and durable antitumor activity with manageable and tolerable safety profile
  - ORR 24%; CR: 7%
  - Median DOR 8.3 mo
  - Median PFS (4.2 mo) and OS (12.1 mo) encouraging

Clinically meaningful and durable responses observed*

<table>
<thead>
<tr>
<th>Confirmed ORR (95% CI),%</th>
<th>N=101</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR, n (%)</td>
<td>7 (7)</td>
</tr>
<tr>
<td>PR, n (%)</td>
<td>17 (17)</td>
</tr>
<tr>
<td>SD, n (%)</td>
<td>49 (49)</td>
</tr>
<tr>
<td>PD, n (%)</td>
<td>24 (24)</td>
</tr>
<tr>
<td>Not evaluable, n (%)</td>
<td>4 (4)</td>
</tr>
</tbody>
</table>

Median DOR
- Median DOR 8.3 months (4.2-NR)

*Data from innovaTV 204 study. Coleman R, et al. Tisotumab Vedotin in Cervically Cancer: Results from the Phase 2 innovaTV 204 / GOG-3023/ ENGOT-cx6 Study. ESMO September 21, 2020. Data cutoff: February 06, 2020. Median duration of follow-up: 10.0 months. CI, confidence interval; CR, complete response; DOR, duration of response; IRC, independent review committee; NR, not reached; ORR, objective response rate; PD, disease progression; PR, partial response; SD, stable disease.
Over 17k Patients Treated for Metastatic Cervical Cancer (mCC) in US, EU5 and Japan

Addressable mCC active patients: >17.5k

1L patients: 11,531
2L patients: 4,513
3L+ Patients: 1,419

US: 4,495
EU5: 4,467
Japan: 2,569

US: 1,825
EU5: 1,652
Japan: 1,036

US: 600
EU5: 521
Japan: 298

Source: Kantar Health Drug Treated Patients (2020 Report);
Our Goal in Cervical Cancer: Establish Tisotumab Vedotin as the Clear Choice in 2L+ Settings

mCC Treatment Landscape

1L
Chemotherapy +/- Bevacizumab*

2L
~50% PD-L1+
Pembro**, Other IO, or Chemo

~50% PD-L1-

3L+
Pembrolizumab or Chemotherapy

Source: Kantar Treatment Architecture: Cervical Cancer; NCCN Treatment Guidelines; 2020 TV ATU (Strategic Research Insights)

*Pembrolizumab & other IOs are being evaluated in 1L treatment

**Pembrolizumab is approved for 2L r/mCC in the US; not approved in JPN or EU
Positive Perception of Next-Gen CD3xCD20 Bispecifics & Potential to Transform B-cell Malignancy Treatment

<table>
<thead>
<tr>
<th>B-NHL Type</th>
<th>Intervention</th>
<th>Study Phase</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Preclinical</td>
<td>I</td>
</tr>
<tr>
<td>DLBCL, FL, MCL and other histologies</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Front-line</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DLBCL</td>
<td>Epcoritamab + R-CHOP</td>
<td>GCT3013-02</td>
<td>Ph Ib</td>
</tr>
<tr>
<td>FL</td>
<td>Epcoritamab + BR</td>
<td>GCT3013-02</td>
<td>Ph Ib</td>
</tr>
<tr>
<td><strong>Relapsed or refractory</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DLBCL</td>
<td>Epcoritamab vs SOC</td>
<td>GCT3013-05</td>
<td>Ph III</td>
</tr>
<tr>
<td>B-NHL (DLBCL, FL, MCL)</td>
<td>Epcoritamab monotherapy</td>
<td>GCT3013-01</td>
<td>Ph I/II</td>
</tr>
<tr>
<td>B-NHL (Japanese patients)</td>
<td>Epcoritamab monotherapy</td>
<td>GCT3013-04</td>
<td>Ph I/II</td>
</tr>
<tr>
<td>ASCT eligible DLBCL</td>
<td>Epcoritamab + R-DHAX/C</td>
<td>GCT3013-02</td>
<td>Ph Ib</td>
</tr>
<tr>
<td>FL</td>
<td>Epcoritamab + GemOx</td>
<td>GCT3013-02</td>
<td>Ph Ib</td>
</tr>
<tr>
<td>CLL</td>
<td>Epcoritamab + R²</td>
<td>GCT3013-03</td>
<td>Ph Ib</td>
</tr>
</tbody>
</table>

B-NHL: B-cell Non-Hodgkin Lymphoma; BR: bendamustine + rituximab; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; MCL: mantle cell lymphoma; SOC: standard of care; R² = Revlimid + rituximab

For investor audience only. Not for public information or use. Not for promotional use.
HexaBody-CD38 (GEN3014)

Expanding the potential of CD38 antibodies

- Incorporates proprietary HexaBody technology
- Highly promising data pre-clinical models for MM, lymphoma & AML
- Could potentially add to and broaden DARZALEX franchise
- IND filed Q4 2020
DARZALEX Approvals: US and EU
On Track for Approval Across All Lines of MM Treatment

US Approvals

- November 2015, Monotherapy (SIRIUS)
- November 2016, RRMM (CASTOR; POLLUX), D-Vd, D-Rd
- June 2017, RRMM (EQUULEUS), D-Pd
- May 2018, FLMM NTE (ALCYONE), D-VMP
- February 2019, Split dosing
- June 2019, FLMM NTE (MAIA), D-Rd
- September 2019, FLMM TE (CASSIOPEIA), D-VTd
- May 2020, DARZALEX FASPRO (COLUMBA; PLEIADES) Subcutaneous
- August 2020, RRMM (APOLLO), SubQ D-Pd, Nov. 2020

EU Approvals

- April 2016, Monotherapy (SIRIUS)
- February 2017, RRMM (CASTOR; POLLUX), D-Vd, D-Rd
- June 2018, FLMM NTE (ALCYONE), D-VMP
- December 2018, Split dosing
- November 2019, FLMM NTE (MAIA), D-Rd
- January 2020, FLMM TE (CASSIOPEIA), D-VTd
- June 2020, Subcutaneous (COLUMBA; PLEIADES)

For Investor audience only. Not for public information or use. Not for promotional use.
# Ongoing Daratumumab Clinical Trials

## Janssen Sponsored Phase 3 & 4

### Daratumumab Trials Sponsored by Pharma / Biotech

<table>
<thead>
<tr>
<th>Ct.gov Identifier</th>
<th>Phase</th>
<th>Sponsor</th>
<th>Indication</th>
<th>Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03768960</td>
<td>4</td>
<td>J&amp;J Private Ltd</td>
<td>Relapsed or Refractory MM</td>
<td>Daratumumab (MMY4008)</td>
</tr>
<tr>
<td>NCT02252172</td>
<td>3</td>
<td>Janssen</td>
<td>Untreated MM</td>
<td>Daratumumab + Rd (MAIA)</td>
</tr>
<tr>
<td>NCT02195479</td>
<td>3</td>
<td>Janssen</td>
<td>Untreated MM</td>
<td>Daratumumab + VMP (ALCYONE)</td>
</tr>
<tr>
<td>NCT02541383</td>
<td>3</td>
<td>Janssen</td>
<td>Untreated MM</td>
<td>Daratumumab + VTd (CASSIOPEIA)</td>
</tr>
<tr>
<td>NCT02076009</td>
<td>3</td>
<td>Janssen</td>
<td>Relapsed or Refractory MM</td>
<td>Daratumumab + Rd (POLLUX)</td>
</tr>
<tr>
<td>NCT02136134</td>
<td>3</td>
<td>Janssen</td>
<td>Relapsed or Refractory MM</td>
<td>Daratumumab + Vd (CASTOR)</td>
</tr>
<tr>
<td>NCT03180736</td>
<td>3</td>
<td>Janssen</td>
<td>Relapsed or Refractory MM</td>
<td>Daratumumab + Pom-d (APOLLO)</td>
</tr>
<tr>
<td>NCT03201965</td>
<td>3</td>
<td>Janssen</td>
<td>Amyloidosis</td>
<td>Daratumumab + CyBorD (ANDROMEDA)</td>
</tr>
<tr>
<td>NCT03217812</td>
<td>3</td>
<td>Janssen</td>
<td>Untreated MM</td>
<td>Daratumumab + VMP (Asia Pacific) (OCTANS)</td>
</tr>
<tr>
<td>NCT03234972</td>
<td>3</td>
<td>Janssen</td>
<td>Relapsed or Refractory MM</td>
<td>Daratumumab + Vd vs Vd (LEPUS)</td>
</tr>
<tr>
<td>NCT03277105</td>
<td>3</td>
<td>Janssen</td>
<td>Relapsed or Refractory MM</td>
<td>Daratumumab SubQ vs IV (COLUMBA)</td>
</tr>
<tr>
<td>NCT03301220</td>
<td>3</td>
<td>Janssen</td>
<td>Smoldering MM</td>
<td>Daratumumab SubQ (AQUILA)</td>
</tr>
<tr>
<td>NCT03652064</td>
<td>3</td>
<td>Janssen</td>
<td>Untreated MM</td>
<td>Daratumumab + VRd (CEPHEUS)</td>
</tr>
<tr>
<td>NCT03710603</td>
<td>3</td>
<td>Janssen/EMN</td>
<td>Untreated MM</td>
<td>Daratumumab + VRd (PERSEUS)</td>
</tr>
<tr>
<td>NCT03901963</td>
<td>3</td>
<td>Janssen</td>
<td>Untreated MM / Maintenance</td>
<td>Daratumumab + R (AURIGA)</td>
</tr>
</tbody>
</table>